Updated at 12:03 p.m.
Generic drugmaker Mylan NV, which has been under fire for its price hikes on the life-saving EpiPen allergy treatment, said on Wednesday that it would restructure and expected to cut less than 10 percent of its global workforce as it integrates acquisitions.
Mylan, whose shares were down more than 4 percent at midday, has been under investigation by the U.S. government, and its chief executive officer was called before Congress to testify on raising the price of a pair of EpiPens to more than $600 from $100 in 2008.
The company said in a regulatory fil…
Read the full article at: http://www.stltoday.com/business/local/epipen-maker-mylan-to-restructure-and-cut-its-workforce/article_6a420463-15cc-56eb-9c51-68ee11386a69.html